These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39306895)

  • 21. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More cost-sharing, less cost? Evidence on reference price drugs.
    Herr A; Stühmeier T; Wenzel T
    Health Econ; 2023 Feb; 32(2):413-435. PubMed ID: 36415146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses.
    Serra-Burriel M; Martin-Bassols N; Perényi G; Vokinger KN
    JAMA Health Forum; 2024 Aug; 5(8):e242530. PubMed ID: 39150730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
    Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
    JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
    Alrasheed M; Hincapie AL; Guo JJ
    J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generic Drugs in the United States: Policies to Address Pricing and Competition.
    Gupta R; Shah ND; Ross JS
    Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States.
    Alpern JD; Zhang L; Stauffer WM; Kesselheim AS
    Clin Infect Dis; 2017 Nov; 65(11):1848-1852. PubMed ID: 29020146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shortages of antiseizure medications in Australia and the association with patient switching, and adherence in a community setting.
    Welton J; Stratton G; Schoeninger B; Low MH; Moody A; D'Souza W
    Epilepsy Behav; 2023 Apr; 141():109145. PubMed ID: 36913876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
    Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
    J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commentary: Consensus Guidelines on the Appropriate Use of Brand-Name and Generic Anti-Seizure Medication for the Management of Epilepsy in the Gulf Region.
    Alsaadi T; Almadani A; Al-Hashel J; Al Salti A; Melikyan G; Khan RA
    Neurol Ther; 2023 Aug; 12(4):1015-1031. PubMed ID: 37222860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
    Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
    BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications.
    Mattingly TJ; Anderson GF; Levy JF
    JAMA Health Forum; 2023 Jun; 4(6):e231317. PubMed ID: 37294584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone.
    Rome BN; Egilman AC; Patel NG; Kesselheim AS
    Value Health; 2023 Mar; 26(3):370-377. PubMed ID: 36266218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of United States and canadian glaucoma medication costs and price change from 2006 to 2013.
    Schlenker MB; Trope GE; Buys YM
    J Ophthalmol; 2015; 2015():547960. PubMed ID: 25922760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.